The particular relationship between Parkinson's disease and malignancy: A focus on skin cancers

Journal of Neural Transmission

Volumn 116, Issue 11, 2009, Pages 1503-1507

  Inzelberg, Rivka ^a,b   Israeli Korn, Simon D ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer; Melanoma; Parkinson's disease; Skin cancer

Indexed keywords

LEVODOPA;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENE INTERACTION; HUMAN; MELANOMA; PARKINSON DISEASE; PRECANCER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SKIN CANCER; SKIN EXAMINATION;

ANTIPARKINSON AGENTS; CAUSALITY; COMORBIDITY; HUMANS; LEVODOPA; MASS SCREENING; MELANOMA; PARKINSON DISEASE; RISK FACTORS; SKIN NEOPLASMS;

EID: 70449520090     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-009-0322-x     Document Type: Review

References (48)

1. PD Baade L Fritschi DM Freedman 2007 Mortality due to amyotrophic lateral sclerosis and Parkinson's disease among melanoma patients Neuroepidemiology 28 16 20 10.1159/000097851 1:STN:280:DC%2BD2s%2FotlGjsQ%3D%3D 17164565 (Pubitemid 46221024)
2. Y Ben-Shlomo MG Marmot 1995 Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58 293 299 10.1136/jnnp.58.3.293 1:STN:280:DyaK2M3gsFWnug%3D%3D 7897409
3. JM Bertoni JP Arlette HH Fernandez K Frei M Gordon M Hassan 2006 Epidemiologic association of Parkinson's disease and melanoma Mov Disord 21 Suppl 15 S610
4. D Chakroborty UR Chowdhury C Sarkar R Baral PS Dasgupta S Basu 2008 Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization J Clin Invest 118 1380 1389 10.1172/JCI33125 1:CAS:528:DC%2BD1cXkt1CntbY%3D 18340382
5. R Constantinescu M Romer K Kieburtz 2007 Malignant melanoma in early Parkinson's disease: the DATATOP trial Mov Disord 22 720 722 10.1002/mds.21273 17373726 (Pubitemid 46800147)
6. M D'Amelio P Ragonese G Sconzo P Aridon G Savettieri 2009 Parkinson's disease and cancer: insights for pathogenesis from epidemiology Ann N Y Acad Sci 1155 324 334 10.1111/j.1749-6632.2008.03681.x 19250224
7. H Deng W Le Y Guo CB Hunter W Xie M Huang J Jankovic 2006 Genetic analysis of LRRK2 mutations in patients with Parkinson disease J Neurol Sci 251 102 106 10.1016/j.jns.2006.09.017 1:CAS:528:DC%2BD28Xht1Chs7zF 17097110 (Pubitemid 44792149)
8. LJ Doshay 1954 Problem situations in paralysis agitans JAMA 156 680 683 1:STN:280:DyaG2M%2Fht12ktw%3D%3D
9. JA Driver G Logroscino JE Buring JM Gaziano T Kurth 2007 A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease Cancer Epidemiol Biomarkers Prev 16 1260 1265 10.1158/1055-9965.EPI-07-0038 17548694 (Pubitemid 46984968)
10. JA Driver T Kurth JE Buring JM Gaziano G Logroscino 2007 Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease Cancer Causes Control 18 705 711 10.1007/s10552-007-9005-9 17562193 (Pubitemid 46988238)
11. A Elbaz BJ Peterson P Yang JAV Van Gerpen JH Bower DM Maraganore SK McDonnell JE Ahlkog WA Rocca 2002 Nonfatal cancer preceding Parkinson's disease Epidemiology 13 157 164 10.1097/00001648-200203000-00010 11880756 (Pubitemid 34160490)
12. A Elbaz BJ Peterson JH Bower P Yang DM Maraganore SK McDonnell 2005 Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort Mov Disord 30 719 725 10.1002/mds.20401 (Pubitemid 41051783)
13. J Ferreira JM Silva R Freire J Pignatelli LC Guedes A Feijó MM Rosa M Coelho J Costa A Noronha R Hewett AM Gomes JL Cirne de Castro O Rascol C Sampaio 2007 Skin cancers and precancerous lesions in Parkinson's Disease patients Mov Disord 22 1471 1475 10.1002/mds.21575 17516496 (Pubitemid 47280634)
14. KH Fiala J Whetteckey BV Manyam 2003 Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonism Relat Disord 9 321 327 10.1016/S1353-8020(03)00040-3 12853231 (Pubitemid 36809033)
15. X Gao KC Simon J Han MA Schwarzschild A Ascherio 2009 Genetic determinants of hair color and Parkinson's disease risk Ann Neurol 65 76 82 10.1002/ana.21535 19194882
16. JM Gorrell CC Johnson BA Rybicki 1994 PD and its comorbid disorders Neurology 44 1865 1868
17. H Gurney A Coates R Kefford 1991 The use of l-dopa and carbidopa in metastatic malignant melanoma J Invest Dermatol 96 85 87 10.1111/1523-1747. ep12515896 1:STN:280:DyaK3M7gtVyhtA%3D%3D 1987300
18. SA Haider VT Thaller 1992 Lid melanoma and parkinsonism Br J Ophthalmol 76 246 247 10.1136/bjo.76.4.246 1:STN:280:DyaK3s%2Fgt1yhsA%3D%3D 1390497
19. H Harada S Nishikawa K Takahashi 1983 Epidemiology of Parkinson's disease in a Japanese city Arch Neurol 40 151 154 1:STN:280:DyaL3s7lt1emtg%3D%3D 6830454
20. S Hassin-Baer Y Laitman E Azizi I Molchadski G Galore-Haskel F Barak OS Cohen E Friedman 2009 The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel J Neurol 256 483 487 10.1007/s00415-009-0117-x 1:CAS:528:DC%2BD1MXltlKrsrs%3D 19412725
21. E Herrero Hernández 2009 Pigmentation as a clue to understanding Parkinson's disease and melanoma Ann Neurol 65 759 10.1002/ana.21688 19557863
22. MM Hoehn MD Yahr 1967 Parkinsonism: onset, progression and mortality Neurology 17 427 442 1:STN:280:DyaF2s7jvFSgsg%3D%3D 6067254
23. R Inzelberg J Jankovic 2007 Are Parkinson disease patients protected from some but not all cancers? Neurology 69 1542 1550 10.1212/01.wnl.0000277638. 63767.b8 17699801 (Pubitemid 47537862)
24. R Inzelberg J Jankovic 2008 Are Parkinson disease patients protected from some but not all cancers? Neurology 71 1650 1651 10.1212/01.wnl.0000339367. 54460.8c
25. R Inzelberg JM Rabey R Djaldetti A Reches S Badarny S Hassin-Baer H Trau J Aharon-Peretz M Huberman L Gilead N Giladi 2007 Elevated prevalence of malignant melanoma in Israeli patients with Parkinson's disease Mov Disord 22 Suppl 16 S169 S170
26. B Jansson J Jankovic 1985 Low cancer rates among patients with Parkinson's disease Ann Neurol 17 505 509 10.1002/ana.410170514 1:STN:280:DyaL2M3itl2nug%3D%3D 4004173 (Pubitemid 15019991)
27. J Kincannon C Boutzale 1999 The physiology of pigmented nevi Pediatrics 104 1042 1045 1:STN:280:DyaK1Mvjs1Cnuw%3D%3D 10506262
28. Y Minami R Yamamoto M Nishikouri A Fukao S Hisamichi 2000 Mortality and cancer in Parkinson's disease J Neurol 247 429 434 10.1007/s004150070171 1:STN:280:DC%2BD3M%2FktVygtg%3D%3D 10929271 (Pubitemid 30433556)
29. H Moller L Mellemkjaer JK McLaughlin JH Olsen 1995 Occurrence of different cancers in Parkinson's disease Br Med J 310 1500 1501 1:STN:280:DyaK2Mzgslakuw%3D%3D
30. JH Olsen 1997 Avoidable cancers in the Nordic countries. Aims and background APMIS Suppl 76 1 8 1:STN:280:DyaK1c7it1Knuw%3D%3D 9462817
31. JH Olsen S Friis K Frederiksen JK McLaughlin L Mellemkjaer H Moller 2005 Atypical cancer pattern in patients with Parkinson's disease Br J Cancer 92 201 205 10.1038/sj.bjc.6602279 1:STN:280:DC%2BD2M%2Fnt1SntA%3D%3D 15583688 (Pubitemid 40188456)
32. JH Olsen S Friis K Frederiksen 2006 Malignant melanoma and other types of cancer preceding Parkinson disease Epidemiology 17 582 587 10.1097/01.ede. 0000229445.90471.5e 16837822 (Pubitemid 44223068)
33. JH Olsen K Tangerud L Wermuth K Frederiksen S Friis 2007 Treatment with levodopa and risk for malignant melanoma Mov Disord 22 1252 1257 10.1002/mds.21397 17534943 (Pubitemid 47325031)
34. W Pfutzner B Przybilla 1997 Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature J Am Acad Dermatol 37 332 336 10.1016/S0190-9622(97)70020-3 1:STN:280:DyaK2svhs1Gqsw%3D%3D 9270541
35. PB Pritchard III MG Netsky 1973 Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study Neurology 23 215 222 4144412
36. FH Rampen 1985 Levodopa and melanoma: three cases and review of literature J Neurol Neurosurg Psychiatry 48 585 588 10.1136/jnnp.48.6.585 1:STN:280:DyaL2M3js1ertg%3D%3D 4009196
37. DS Rigel Z Patel J Bolognia C Eichler DL Ellis RJ Friedman 2006 Evaluation of Parkinson's disease (PD) prevalence in patients with malignant melanoma Mov Disord 21 suppl 13 S58
38. R Sandyk 1992 Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland Int J Neurosci 63 137 140 1:STN:280:DyaK2c%2FpsFeguw%3D%3D 1342025
39. C Sarkar D Chakroborty UR Chowdhury PS Dasgupta S Basu 2008 Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models Clin Cancer Res 14 2502 2510 10.1158/1078-0432.CCR-07-1778 1:CAS:528:DC%2BD1cXkvFGmurs%3D 18413843 (Pubitemid 351551086)
40. JF Siple DC Schneider WA Wanlass BK Rosenblatt 2000 Levodopa therapy and the risk of malignant melanoma Ann Pharmacother 34 382 385 10.1345/aph.19150 1:CAS:528:DC%2BD3cXitVCgsr4%3D 10917387
41. JL Skibba J Pinckley EF Gilbert RO Johnson 1972 Multiple primary melanoma following administration of levodopa Arch Pathol 93 556 561 1:STN:280:DyaE387otFWluw%3D%3D 5025039
42. AJ Sober MM Wick 1978 Levodopa therapy and malignant melanoma JAMA 240 554 555 10.1001/jama.240.6.554 1:STN:280:DyaE1c3itV2lsg%3D%3D 671667 (Pubitemid 9058780)
43. AJ Strongosky M Farrer ZK Wszolek 2008 Are Parkinson disease patients protected from some but not all cancers? Neurology 71 1650 10.1212/01.wnl. 0000339367.54460.8c 19001259
44. H Tomiyama Y Li M Funayama K Hasegawa H Yoshino S Kubo K Sato T Hattori CS Lu R Inzelberg R Djaldetti E Melamed R Amouri N Gouider-Khouja F Hentati Y Hatano M Wang Y Imamichi K Mizoguchi H Miyajima F Obata T Toda MJ Farrer Y Mizuno N Hattori 2006 Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries Mov Disord 21 1102 1108 10.1002/mds.20886 16622854 (Pubitemid 44336593)
45. N Vanacore S Spila-Alegiani R Raschetti G Meco 1999 Mortality cancer risk in parkinsonian patients: a population-based study Neurology 52 395 398 1:STN:280:DyaK1M7ivFOntw%3D%3D 9932965
46. K Westlund A Hougen 1956 Cancer as a cause of death among patients with other chronic diseases JAMA 162 1003 1008
47. Zanetti R, Rosso S (2007) Levodopa and the risk of melanoma. Lancet 369:9558
48. R Zanetti D Loria S Rosso 2006 Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature Melanoma Res 16 201 206 10.1097/01.cmr.0000215043.61306.d7 1:CAS:528:DC%2BD28Xksl2hsLw%3D 16718266 (Pubitemid 44085093)